Resources from IPC and trusted sources to assist people with psoriasis in navigating the COVID-19 pandemic.
Available resources to help individuals with psoriasis better understand the risks associated with monkeypox.
The COVID-19 pandemic has raised concerns for individuals with psoriasis, who may question how the virus could affect them. To address these concerns, IPC has compiled a range of resources from trusted sources to assist those with psoriasis in navigating this challenging time. These resources provide information on the latest COVID-19 updates, advice on managing psoriasis during the pandemic, and guidance on mental health and well-being.
Read the statement from IPC’s Board of Directors based on the current understanding of the impact of COVID-19 and psoriasis.
PsoProtect is an international registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. The registry seeks to improve our understanding of how factors such as immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis. This information will inform clinicians when assessing risk and treating COVID-19 in patients with psoriasis.
Monkeypox is a rare viral disease that can be particularly concerning for individuals with psoriasis due to their weakened immune systems. These resources aim to help those with psoriasis better understand the risks associated with monkeypox, including information on symptoms, diagnosis, and treatment options. We encourage individuals with psoriasis to explore these resources and consult a healthcare professional for personalized guidance on managing their condition.
Below are resources from other organizations that examine the relationship between monkeypox and psoriasis.
Atlas of MPOX Lesions: A Tool for Clinical Researchers. World Health Organization. Version 1.0. World Health Organization, 2023. Accessed April 28, 2023.
Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 Pandemic